Citius Pharmaceuticals (CTXR) vs Lisata Therapeutics (LSTA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Lisata Therapeutics (LSTA) has outperformed Citius Pharmaceuticals (CTXR) over the past year, losing 52.6% versus a loss of 62.0%. Over five years, LSTA leads with a -93.4% price change compared with -99.0% for CTXR. Citius Pharmaceuticals is the larger company by market cap ($13.4 million vs $13.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CTXR | LSTA |
|---|---|---|
| Share price | $0.4887 | $1.20 |
| Market cap | $13.42M | $12.96M |
| 1-day change | -2.47% | +2.56% |
| YTD return | -37.10% | -35.48% |
| 1-year return | -61.97% | -52.57% |
| 5-year return | -99.04% | -93.44% |
| EPS (TTM) | $-1.75 | $-1.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.19 | $5.07 |
| 52-week low | $0.469 | $0.99 |
| Distance from 52-week high | -77.68% | -76.33% |
| Analyst consensus | none | none |
| Avg. price target upside | +718.50% | — |
| Average volume | 528.79K | 291.91K |
| Shares outstanding | 27.45M | 10.80M |
| Employees | 23 | 21 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Citius Pharmaceuticals
CTXR stock →Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma.
Healthcare · Biotechnology · 23 employees
About Lisata Therapeutics
LSTA stock →Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens.
Healthcare · Biotechnology · 21 employees
CTXR vs LSTA FAQ
Which is bigger, Citius Pharmaceuticals or Lisata Therapeutics?
Citius Pharmaceuticals (CTXR) is larger, with a market capitalization of $13.42M compared with $12.96M for Lisata Therapeutics (LSTA).
Which stock has performed better over the past year, CTXR or LSTA?
LSTA returned -52.57% over the past 12 months, compared with -61.97% for CTXR (price return, excluding dividends). Past performance does not predict future results.
Are Citius Pharmaceuticals and Lisata Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.